Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag for Chemotherapy-induced Thrombocytopenia in Solid Tumors
NCT05236582Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hetrombopag in chemotherapy-induced thrombocytopenia (CIT), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Changes of the platelet counts after the treatment of Herombopag at 12 weeks. Started Mar 2022; status: recruiting.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT05236582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236582.